Role of CD47 in Hematological Malignancies
Abstract CD47, or integrin-associated protein, is a cell surface ligand expressed in low levels by nearly all cells of the body. It plays an integral role in various immune responses as well as autoimmunity, by sending a potent “don’t eat me” signal to prevent phagocytosis. A growing body of evidenc...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2020-07-01
|
| Series: | Journal of Hematology & Oncology |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s13045-020-00930-1 |
| _version_ | 1811223419541258240 |
|---|---|
| author | Entsar Eladl Rosemarie Tremblay-LeMay Nasrin Rastgoo Rumina Musani Wenming Chen Aijun Liu Hong Chang |
| author_facet | Entsar Eladl Rosemarie Tremblay-LeMay Nasrin Rastgoo Rumina Musani Wenming Chen Aijun Liu Hong Chang |
| author_sort | Entsar Eladl |
| collection | DOAJ |
| description | Abstract CD47, or integrin-associated protein, is a cell surface ligand expressed in low levels by nearly all cells of the body. It plays an integral role in various immune responses as well as autoimmunity, by sending a potent “don’t eat me” signal to prevent phagocytosis. A growing body of evidence demonstrates that CD47 is overexpressed in various hematological malignancies and its interaction with SIRPα on the phagocytic cells prevents phagocytosis of cancer cells. Additionally, it is expressed by different cell types in the tumor microenvironment and is required for establishing tumor metastasis. Overexpression of CD47 is thus often associated with poor clinical outcomes. CD47 has emerged as a potential therapeutic target and is being investigated in various preclinical studies as well as clinical trials to prove its safety and efficacy in treating hematological neoplasms. This review focuses on different therapeutic mechanisms to target CD47, either alone or in combination with other cell surface markers, and its pivotal role in impairing tumor growth and metastatic spread of various types of hematological malignancies. |
| first_indexed | 2024-04-12T08:32:37Z |
| format | Article |
| id | doaj.art-19584355cd4743fc97cf34262e6e29a0 |
| institution | Directory Open Access Journal |
| issn | 1756-8722 |
| language | English |
| last_indexed | 2024-04-12T08:32:37Z |
| publishDate | 2020-07-01 |
| publisher | BMC |
| record_format | Article |
| series | Journal of Hematology & Oncology |
| spelling | doaj.art-19584355cd4743fc97cf34262e6e29a02022-12-22T03:40:07ZengBMCJournal of Hematology & Oncology1756-87222020-07-0113111410.1186/s13045-020-00930-1Role of CD47 in Hematological MalignanciesEntsar Eladl0Rosemarie Tremblay-LeMay1Nasrin Rastgoo2Rumina Musani3Wenming Chen4Aijun Liu5Hong Chang6Laboratory Medicine Program, Toronto General Hospital, University Health Network, University of TorontoLaboratory Medicine Program, Toronto General Hospital, University Health Network, University of TorontoLaboratory Medicine Program, Toronto General Hospital, University Health Network, University of TorontoLaboratory Medicine Program, Toronto General Hospital, University Health Network, University of TorontoDepartment of Hematology, Beijing Chaoyang Hospital, Capital UniversityDepartment of Hematology, Beijing Chaoyang Hospital, Capital UniversityLaboratory Medicine Program, Toronto General Hospital, University Health Network, University of TorontoAbstract CD47, or integrin-associated protein, is a cell surface ligand expressed in low levels by nearly all cells of the body. It plays an integral role in various immune responses as well as autoimmunity, by sending a potent “don’t eat me” signal to prevent phagocytosis. A growing body of evidence demonstrates that CD47 is overexpressed in various hematological malignancies and its interaction with SIRPα on the phagocytic cells prevents phagocytosis of cancer cells. Additionally, it is expressed by different cell types in the tumor microenvironment and is required for establishing tumor metastasis. Overexpression of CD47 is thus often associated with poor clinical outcomes. CD47 has emerged as a potential therapeutic target and is being investigated in various preclinical studies as well as clinical trials to prove its safety and efficacy in treating hematological neoplasms. This review focuses on different therapeutic mechanisms to target CD47, either alone or in combination with other cell surface markers, and its pivotal role in impairing tumor growth and metastatic spread of various types of hematological malignancies.http://link.springer.com/article/10.1186/s13045-020-00930-1CD47ImmunotherapyTargeted therapyHematological cancers |
| spellingShingle | Entsar Eladl Rosemarie Tremblay-LeMay Nasrin Rastgoo Rumina Musani Wenming Chen Aijun Liu Hong Chang Role of CD47 in Hematological Malignancies Journal of Hematology & Oncology CD47 Immunotherapy Targeted therapy Hematological cancers |
| title | Role of CD47 in Hematological Malignancies |
| title_full | Role of CD47 in Hematological Malignancies |
| title_fullStr | Role of CD47 in Hematological Malignancies |
| title_full_unstemmed | Role of CD47 in Hematological Malignancies |
| title_short | Role of CD47 in Hematological Malignancies |
| title_sort | role of cd47 in hematological malignancies |
| topic | CD47 Immunotherapy Targeted therapy Hematological cancers |
| url | http://link.springer.com/article/10.1186/s13045-020-00930-1 |
| work_keys_str_mv | AT entsareladl roleofcd47inhematologicalmalignancies AT rosemarietremblaylemay roleofcd47inhematologicalmalignancies AT nasrinrastgoo roleofcd47inhematologicalmalignancies AT ruminamusani roleofcd47inhematologicalmalignancies AT wenmingchen roleofcd47inhematologicalmalignancies AT aijunliu roleofcd47inhematologicalmalignancies AT hongchang roleofcd47inhematologicalmalignancies |